Relutrigine

Name: Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Prevalence of SCN2A- and SCN8A-related developmental and epileptic encephalopathies
Published: 2026-09-14T15:39:06-04:00

SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Manufacturer: Praxis Precision Medicines
Regulatory submission: NDA submitted in early 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Epidemiology

Prevalence of SCN2A- and SCN8A-related developmental and epileptic encephalopathies

2 evidence topics · 3 sources

Epidemiology: combined SCN2A and SCN8A population, manufacturer estimate

“Estimated prevalence of ~5,000 patients in the US” (opens the source at this quote in a new tab)

Epidemiology: SCN8A-related epilepsy and neurodevelopmental disorders

“The prevalence of SCN8A-related epilepsy and/or neurodevelopmental disorders is not known.” (opens the source at this quote in a new tab)